Inhaled antibiotics beyond aminoglycosides, polymyxins and aztreonam: A systematic review

International Journal of Antimicrobial Agents

Volumn 45, Issue 3, 2015, Pages 221-233

  Falagas, Matthew E ^a,b,c   Trigkidis, Kyriakos K ^a   Vardakas, Konstantinos Z ^a,b  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aerosolised antibiotics; Hospital acquired pneumonia; Nebulised antibiotics; Nosocomial pneumonia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; CARBENICILLIN; CEFALORIDINE; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; OXACILLIN; PENICILLIN DERIVATIVE; PLACEBO; POLYMYXIN; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; SULBACTAM; SULTAMICILLIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; BETA LACTAM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BRONCHIECTASIS; BRONCHOSPASM; BURKHOLDERIA CEPACIA INFECTION; CLINICAL EVALUATION; COLONY FORMING UNIT; CYSTIC FIBROSIS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FORCED EXPIRATORY FLOW; FORCED VITAL CAPACITY; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INFECTION PREVENTION; LENGTH OF STAY; LOWER RESPIRATORY TRACT INFECTION; OUTCOME ASSESSMENT; PNEUMOTHORAX; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SYSTEMATIC REVIEW; TASTE DISORDER; TRACHEOBRONCHITIS; TREATMENT DURATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VENTILATOR ASSOCIATED PNEUMONIA; WHEEZING; BACTERIAL INFECTIONS; COMPLICATION; INHALATIONAL DRUG ADMINISTRATION; PNEUMONIA, VENTILATOR-ASSOCIATED; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMS; BRONCHIECTASIS; CYSTIC FIBROSIS; FOSFOMYCIN; HUMANS; PNEUMONIA, VENTILATOR-ASSOCIATED; QUINOLONES; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 84923647837     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.10.008     Document Type: Review

References (74)

1. B.S. Quon, C.H. Goss, and B.W. Ramsey Inhaled antibiotics for lower airway infections Ann Am Thorac Soc 11 2014 425 434
2. L.B. Palmer Aerosolized antibiotics in critically ill ventilated patients Curr Opin Crit Care 15 2009 413 418
3. D.E. Geller Aerosol antibiotics in cystic fibrosis Respir Care 54 2009 658 670
4. B.K. Rubin Other medications for aerosol delivery Paediatr Respir Rev 7 2006 S76 S79
5. G.C. Wood, and J.M. Swanson Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia Drugs 67 2007 903 914
6. S. Claus, C. Weiler, J. Schiewe, and W. Friess How can we bring high drug doses to the lung? Eur J Pharm Biopharm 86 2014 1 6
7. M. Ballmann, A. Smyth, and D.E. Geller Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics Respir Med 105 2011 S2 S8
8. M.C. Gaspar, W. Couet, J.C. Olivier, A.A. Pais, and J.J. Sousa Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review Eur J Clin Microbiol Infect Dis 32 2013 1231 1252
9. A.M. Jones, and J.M. Helm Emerging treatments in cystic fibrosis Drugs 69 2009 1903 1910
10. US Food and Drug Administration. Orange book: approved drug products with therapeutic equivalence evaluations. Silver Spring, MD: FDA. http://www.accessdata.fda.gov/scripts/cder/ob/ [accessed 27 October 2014].
11. European Medicines Agency. European Public Assessment Reports Human medicines 2014 EMA London, UK http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar-search.jsp&mid=WC0b01ac058001d124 [accessed 27 October 2014].
12. O.O. Okusanya, S.M. Bhavnani, J.P. Hammel, A. Forrest, C.C. Bulik, and P.G. Ambrose Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies Antimicrob Agents Chemother 58 2014 5005 5015
13. J.P. Clancy, L. Dupont, M.W. Konstan, J. Billings, S. Fustik, and C.H. Goss Arikace Study Group Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection Thorax 68 2014 818 825
14. E. Ioannidou, I.I. Siempos, and M.E. Falagas Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis J Antimicrob Chemother 60 2007 1216 1226
15. A.M. Brodt, E. Stovold, and L. Zhang Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review Eur Respir J 44 2014 382 393
16. M.L. Metersky New treatment options for bronchiectasis Ther Adv Respir Dis 4 2010 93 99
17. M. Hoppentocht, P. Hagedoorn, H.W. Frijlink, and A.H. de Boer Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: a critical evaluation Eur J Pharm Biopharm 86 2014 23 30
18. A.J. Hickey, A. Misra, and P.B. Fourie Dry powder antibiotic aerosol product development: inhaled therapy for tuberculosis J Pharm Sci 102 2013 3900 3907
19. B.J. Rijnders, J.J. Cornelissen, L. Slobbe, M.J. Becker, J.K. Doorduijn, and W.C. Hop Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial Clin Infect Dis 46 2008 1401 1408
20. V. Monforte, P. Ussetti, J. Gavaldà, C. Bravo, R. Laporta, and O. Len Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation J Heart Lung Transplant 29 2010 523 530
21. S.M. Shankar, and J.J. Nania Management of Pneumocystis jiroveci pneumonia in children receiving chemotherapy Paediatr Drugs 9 2007 301 309
22. K. McKeage Tobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis Drugs 73 2013 1815 1827
23. M.P. Murray, J.R. Govan, C.J. Doherty, A.J. Simpson, T.S. Wilkinson, and J.D. Chalmers A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis Am J Respir Crit Care Med 183 2011 491 499
24. M.W. Konstan, P.A. Flume, M. Kappler, R. Chiron, M. Higgins, and F. Brockhaus Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial J Cyst Fibros 10 2011 54 61
25. A. Schuster, C. Haliburn, G. Doring, and M.H. Goldman Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study Thorax 68 2014 344 350
26. A. Michalopoulos, and E. Papadakis Inhaled anti-infective agents: emphasis on colistin Infection 38 2010 81 88
27. H.A. Tiddens, K. De Boeck, J.P. Clancy, M. Fayon, H.G.M. Arets, and M. Bresnik ALPINE Study Investigators Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: the ALPINE study J Cyst Fibros 2014 10.1016/j.jcf.2014.06.003 [Epub ahead of print]
28. D. Hutchinson, M. Barclay, W.A. Prescott, and J. Brown Inhaled aztreonam lysine: an evidence-based review Expert Opin Pharmacother 14 2013 2115 2124
29. J.A. Claridge, N.M. Edwards, J. Swanson, T.C. Fabian, J.A. Weinberg, and C. Wood Aerosolized ceftazidime prophylaxis against ventilator-associated pneumonia in high-risk trauma patients: results of a double-blind randomized study Surg Infect (Larchmt) 8 2007 83 90
30. G.C. Wood, B.A. Boucher, M.A. Croce, S.D. Hanes, V.L. Herring, and T.C. Fabian Aerosolized ceftazidime for prevention of ventilator-associated pneumonia and drug effects on the proinflammatory response in critically ill trauma patients Pharmacotherapy 22 2002 972 982
31. M. Horianopoulou, M. Kanellopoulou, I. Paraskevopoulos, A. Kyriakidis, N.J. Legakis, and S. Lambropoulos Use of inhaled ampicillin-sulbactam against multiresistant Acinetobacter baumannii in bronchial secretions of intensive care unit patients Clin Microbiol Infect 10 2004 85 86
32. Q. Lu, J. Yang, Z. Liu, C. Gutierrez, G. Aymard, J.J. Rouby Nebulized Antibiotics Study Group Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa Am J Respir Crit Care Med 184 2011 106 115
33. C.P. Stoutenbeek, H.K. van Saene, D.R. Miranda, D.F. Zandstra, and D. Langrehr Nosocomial Gram-negative pneumonia in critically ill patients. A 3-year experience with a novel therapeutic regimen Intensive Care Med 12 1986 419 423
34. M. Radhakrishnan, A. Jaganath, G.S. Rao, and H.B. Kumari Nebulized imipenem to control nosocomial pneumonia caused by Pseudomonas aeruginosa J Crit Care 23 2008 148 150
35. M.E. Hodson, A.R. Penketh, and J.C. Batten Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis Lancet 2 1981 1137 1139
36. R.J. Stead, M.E. Hodson, and J.C. Batten Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa Br J Dis Chest 81 1987 272 279
37. L. Maíz, R. Del Campo, M. Castro, D. Gutiérrez, R. Girón, and R. Cantón Moreno Maintenance treatment with inhaled ampicillin in patients with cystic fibrosis and lung infection due to methicillin-sensitive Staphylococcus aureus Arch Broncopneumol 48 2012 384
38. G. Nolan, P. Moivor, H. Levison, P.C. Fleming, M. Corey, and R. Gold Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin J Pediatr 101 1982 626 630
39. N.N. Huang, E.J. Hiller, C.M. Macri, M. Capitanio, and K.R. Cundy Carbenicillin in patients with cystic fibrosis: clinical pharmacology and therapeutic evaluation J Pediatr 78 1971 338 345
40. M. Wang, W. Ridderberg, C.R. Hansen, N. Høiby, S. Jensen-Fangel, and H.V. Olesen Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis J Cyst Fibros 12 2013 638 643
41. L. Maíz, A. Lamas, A. Fernández-Olmos, L. Suárez, and R. Cantón Unorthodox long-term aerosolized ampicillin use for methicillin-susceptible Staphylococcus aureus lung infection in a cystic fibrosis patient Pediatr Pulmonol 44 2009 512 515
42. A. Weidmann, A.K. Webb, M.E. Dodd, and A.M. Jones Successful treatment of cepacia syndrome with combination nebulised and intravenous antibiotic therapy J Cyst Fibros 7 2008 409 411
43. R. Orriols, J. Roig, J. Ferrer, G. Sampol, A. Rosell, and A. Ferrer Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa Respir Med 93 1999 476 480
44. D.C. Currie, E. Higgs, S. Metcalfe, D.E. Roberts, and P.J. Cole Simple method of monitoring colonising microbial load in chronic bronchial sepsis: pilot comparison of reduction in colonising microbial load with antibiotics given intermittently and continuously J Clin Pathol 40 1987 830 836
45. J.E. Farber, and J. Ross The use of aerosol penicillin and streptomycin in bronchopulmonary infections Calif Med 73 1950 214 217
46. A. Pines, H. Raafat, G.M. Siddiqui, and J.S. Greenfield Treatment of severe Pseudomonas infections of the bronchi Br Med J 1 1970 663 665
47. M.A. el-Din, L.B. Palmer, M.N. el-Tayeb, I. Khalil, and M.S. Gabr Nebulizer therapy with antibiotics in chronic suppurative lung disease J Aerosol Med 7 1994 345 350
48. N. Southwell Inhaled penicillin in bronchial infections Lancet 2 1946 225 227
49. R.A. Stockley, S.L. Hill, and D. Burnett Nebulized amoxicillin in chronic purulent bronchiectasis Clin Ther 7 1985 593 599
50. S.L. Hill, H.M. Morrison, D. Burnett, and R.A. Stockley Short term response of patients with bronchiectasis to treatment with amoxycillin given in standard or high doses orally or by inhalation Thorax 41 1986 559 565
51. L.B. Palmer, G.C. Smaldone, J.J. Chen, D. Baram, T. Duan, and M. Monteforte Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit Crit Care Med 36 2008 2008 2013
52. L.B. Palmer, and G.C. Smaldone Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit Am J Respir Crit Care Med 189 2014 1225 1233
53. C. Wenisch, H. Laferl, M. Szell, K.H. Smolle, A. Grisold, and G. Bertha A holistic approach to MRSA eradication in critically ill patients with MRSA pneumonia Infection 34 2006 148 154
54. A. Solis, D. Brown, J. Hughes, H.K. Van Saene, and D.P. Heaf Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol Pediatr Pulmonol 36 2003 189 195
55. L. Weathers, D. Riggs, M. Santeiro, and R.E. Weibley Aerosolized vancomycin for treatment of airway colonization by methicillin-resistant Staphylococcus aureus Pediatr Infect Dis J 9 1990 220 221
56. J.D. Gradon, E.H. Wu, and L.I. Lutwick Aerosolized vancomycin therapy facilitating nursing home placement Ann Pharmacother 26 1992 209 210
57. D. Hayes Jr., B.S. Murphy, T.W. Mullett, and D.J. Feola Aerosolized vancomycin for the treatment of MRSA after lung transplantation Respirology 15 2010 184 186
58. L. Maíz, R. Cantón, N. Mir, F. Baquero, and H. Escobar Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis Pediatr Pulmonol 26 1998 287 289
59. D.E. Geller, P.A. Flume, D. Staab, R. Fischer, J.S. Loutit, and D.J. Conrad Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa Am J Respir Crit Care Med 183 2011 1510 1516
60. R. Wilson, T. Welte, E. Polverino, A. De Soyza, H. Greville, and A. O'Donnell Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study Eur Respir J 41 2013 1107 1115
61. D.J. Serisier, D. Bilton, A. De Soyza, P.J. Thompson, J. Kolbe, and H.W. Greville Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial Thorax 68 2013 812 817
62. B.C. Trapnell, S.A. McColley, D.G. Kissner, M.W. Rolfe, J.M. Rosen, M. McKevitt Phase 2 FTI Study Group Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with Pseudomonas airway infection Am J Respir Crit Care Med 185 2012 171 178
63. US National Institutes of Health. Clinical trials. https://clinicaltrials.gov/ [accessed 27 October 2014].
64. Yim J-J. Aerosolized vancomycin in methicillin-resistant Staphylococcus aureus pneumonia under mechanical ventilation. NCT01925066. https://clinicaltrials.gov/ct2/show/record/NCT01925066?term=NCT01925066&rank=1 [accessed 27 October 2014].
65. Boyle MP, Dasenbrook E. Persistent methicillin resistant Staphylococcus aureus eradication protocol (PMEP). NCT01594827. https://clinicaltrials.gov/ct2/results?term=NCT01594827&Search=Search [accessed 27 October 2014].
66. Dasenbrook E. Efficacy and safety study of AeroVanc for the treatment of persistent MRSA lung infection in cystic fibrosis patients. NCT01746095. https://clinicaltrials.gov/ct2/show/NCT01746095?term=NCT01746095&rank=1 [accessed 27 October 2014].
67. Flume P. Trial of Aeroquin versus tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients. NCT01270347. https://clinicaltrials.gov/ct2/show/NCT01270347?term=NCT01270347&rank=1 [accessed 27 October 2014].
68. Flume P. MP-376 (Aeroquin™, levofloxacin for inhalation) in patients with cystic fibrosis. NCT01180634. https://clinicaltrials.gov/ct2/show/NCT01180634?term=NCT01180634&rank=1 [accessed 27 October 2014].
69. Froehlich J. Phase 3 study with dual release ciprofloxacin for inhalation in non-CF bronchiectasis (ORBIT-4). NCT02104245. https://clinicaltrials.gov/ct2/show/NCT02104245?term=NCT02104245&rank=1 [accessed 27 October 2014].
70. Director BS. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis (non-CF BE) (RESPIRE 1). NCT01764841. https://clinicaltrials.gov/ct2/show/NCT01764841?term=NCT01764841&rank=1 [accessed 27 October 2014].
71. Director BS. Ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (non-CF BE) (RESPIRE 2). NCT02106832. https://clinicaltrials.gov/ct2/show/NCT02106832?term=%2C+NCT02106832&rank=1 [accessed 27 October 2014].
72. Froehlich J. Phase 3 study with dual release ciprofloxacin for inhalation in non-CF bronchiectasis (ORBIT-3). NCT01515007. https://clinicaltrials.gov/ct2/show/NCT01515007?term=NCT01515007&rank=1 [accessed 27 October 2014].
73. Kollef M. Aerosolized amikacin and fosfomycin in mechanically ventilated patients with Gram-negative pneumonia (IASIS). NCT01969799. https://clinicaltrials.gov/ct2/show/NCT01969799?term=NCT01969799&rank=1 [accessed 27 October 2014].
74. Pharma C. Aerosolized amikacin and fosfomycin in mechanically ventilated patients with Gram-negative and/or Gram-positive bacterial colonization. NCT02218359. https://clinicaltrials.gov/ct2/show/NCT02218359?term=NCT02218359&rank=1 [accessed 27 October 2014].